Aintained following discontinuation. The present study describes a case of recurrent HCC using a portal vein tumor thrombus (PVTT) of your third portal vein right after resection in a patient who was treated with sorafenib and achieved a CR, which was then maintained for more than one year following the discontinuation with the medication. A literature review is also presented. Written informed consent was obtained from the patient. Case report The patient was a 68-year-old male with hepatitis C virus-related liver cirrhosis. A giant HCC was detected and an S7/S8 segmentectomy on the liver was performed at one more hospital. Recurrence in the residual liver, PVTT within the ideal portal branch and suitable abdominal disseminated lesions have been noted 4 months following the CDK7 Synonyms surgery, though only the disseminated lesions have been surgically excised in the request of your patient. The patient was referred to Toho University Healthcare Center, Omori Hospital (Tokyo, Japan) to continue treatment for the intrahepatic recurrence. Inside the initial blood tests in the hospital, liver function was graded as Child-Pugh A and tumor marker levels had been higher: -fetoprotein (AFP), four,773 ng/Correspondenceto: Dr Manabu Watanabe, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Toho University Health-related Center, Omori Hospital, 6-11-1 Omorinishi, Ota-ku, Tokyo 143-8541, Japan E-mail: [email protected] Crucial words: hepatocellular carcinoma, sorafenib, completeresponse, portal vein tumor thrombusSHIOZAWA et al: Full RESPONSE OF HEPATOCELLULAR CARCINOMA FOLLOWING SORAFENIBml; AFP-L3, 60.five ; and des- carboxyprothrombin (DCP), 17,400 mAU/ml (Fig. 1). Abdominal computed tomography (CT) showed a lot of tumors inside the bilateral lobes along with a PVTT within the proper portal branch (Fig. 2). Oral sorafenib therapy was initiated at the suggested dose of 800 mg/day. Grade three hand-foot syndrome (Prevalent Terminology Criteria for Adverse Events version four.0) (five) developed 7 days right after the initiation of sorafenib treatment, plus the dose was decreased to 400 mg/day on day ten. Just after a single month of administration, the AFP level was decreased to 45.7 ng/ml, but there had been no alterations in PVTT or inside the several tumors inside the bilateral lobes on abdominal CT. The condition was judged to be of a steady illness based on the modified Response Evaluation Criteria in Strong Tumors (mRECIST) (6). A partial response was accomplished after six months. On abdominal CT soon after two years of sorafenib administration, multiple tumors within the bilateral lobes had shrunk along with the intense staining on account of the PVTT had been resolved, determined by which the TSH Receptor review situation was judged to have accomplished a CR. Sorafenib at 400 mg/day was continued thereafter, but mild cerebellar infarction created at two years and four months after the initiation of administration, and sorafenib was withdrawn at the request on the patient. A CR was maintained for about one particular year after the discontinuation based on abdominal CT findings and typical tumor marker levels. Discussion Sorafenib can be a multikinase inhibitor with reported activity against Raf-1, B-Raf, vascular endothelial growth factor receptor two (VEGFR2), platelet-derived development aspect receptor (PDGFR) and c-Kit receptors, also as other receptor tyrosine kinases and serine threonine kinases (7). Sorafenib is really a molecular-targeted drug that exerts an antitumor impact by inhibiting tumor development and vascularization. The efficacy of sorafenib has been shown inside the SHARP (two) and AsiaPac.